Immucor competitors

Immucor Competitors include Bio-Rad, Thriva, OncoCyte and hVIVO.
Add company...
Immucor
A global leader in transfusion and transplantation diagnostics.
Bio-Rad
Bio-Rad develops, manufactures, and markets a broad range of products and solutions for the life science research and clinical diagnostics markets.
Thriva
Thriva connects people with their body through finger prick blood tests.
OncoCyte
OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.
hVIVO
hVIVO plc is the name of our LSE AIM-listed business, which was re-named and re-branded from Retroscreen Virology Group plc.
Founding Date
Founding Date
1982
Founding Date
1952
Founding Date
2015
Founding Date
N/A
Founding Date
1998
Type
Type
Private
Type
Public
Type
Private
Type
Public
Type
Public
Tags
Locations
Locations
Norcross, US HQ
Locations
Hercules, US HQ
Villa Ortúzar, AR
Gladesville, AU
Gladesville, AU
Wien, AT
Temse, BE
Vila Sao Francisco (Zona Sul), BR
see more
Locations
Greater London, GB HQ
Locations
Alameda, US HQ
Locations
London, GB HQ
Employees
Employees
9631% increase
Employees
8,1501% decrease
Employees
234% decrease
Employees
15
Employees
25519% decrease
Valuation ($)
Valuation ($)
N/A
Valuation ($)
8.5 b
Valuation ($)
N/A
Valuation ($)
77.3 m
Valuation ($)
57.1 m
Facebook likes
Facebook likes
N/A
Facebook likes
6.5 k
Facebook likes
7.4 k
Facebook likes
45.6 k
Facebook likes
3.4 k
Twitter followers
Twitter followers
160
Twitter followers
45.8 k
Twitter followers
2.5 k
Twitter followers
N/A
Twitter followers
422

Financial

Revenue (est.)
Revenue (est.)
$380m (FY, 2016)
Revenue (est.)
$2.2b (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
£11.9m (FY, 2017)
Cost of goods
Cost of goods
$144m (FY, 2016)
Cost of goods
$972.8m (FY, 2017)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
£8.1m (FY, 2017)
Gross profit
Gross profit
$236m (FY, 2016)
Gross profit
$1.2b (FY, 2017)
Gross profit
N/A
Gross profit
N/A
Gross profit
£3.8m (FY, 2017)
Net income
Net income
($43.8m) (FY, 2016)
Net income
$122.2m (FY, 2017)
Net income
N/A
Net income
($11.2m) (FY, 2016)
Net income
(£9.5m) (FY, 2017)
For sources of this data, please see the company profileDownload Excel

View company profiles

Bio-Rad
HQ
Hercules, US
Employees
8,150↓ 1% decrease

Bio-Rad develops, manufactures, and markets a broad range of products and solutions for the life science research and clinical diagnostics markets.

View company
Thriva
HQ
Greater London, GB
Employees
23↓ 4% decrease

Thriva connects people with their body through finger prick blood tests.

View company
OncoCyte
HQ
Alameda, US
Employees
15

OncoCyte is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.

View company
hVIVO
HQ
London, GB
Employees
255↓ 19% decrease

hVIVO plc is the name of our LSE AIM-listed business, which was re-named and re-branded from Retroscreen Virology Group plc.

View company